Comparative Analysis of E2F Family Member Oncogenic Activity by Chen, Chunxia & Wells, Andrew D.
Comparative Analysis of E2F Family Member Oncogenic
Activity
Chunxia Chen
1, Andrew D. Wells
1,2*
1Joseph Stokes, Jr. Research Institute, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America, 2Department of
Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
The E2F family of transcription factors consists of nine members with both distinct and overlapping functions. These factors are
situated downstream of growth factor signaling cascades, where they play a central role in cell growth and proliferation
through their ability to regulate genes involved in cell cycle progression. For this reason, it is likely that the members of the
E2F family play a critical role during oncogenesis. Consistent with this idea is the observation that some tumors exhibit
deregulated expression of E2F proteins. In order to systematically compare the oncogenic capacity of these family members,
we stably over-expressed E2F1 through 6 in non-transformed 3T3 fibroblasts and assessed the ability of these transgenic cell
lines to grow under conditions of low serum, as well as to form colonies in soft agar. Our results show that these six E2F family
members can be divided into three groups that exhibit differential oncogenic capacity. The first group consists of E2F2 and
E2F3a, both of which have strong oncogenic capacity. The second group consists of E2F1 and E2F6, which were neutral in our
assays when compared to control cells transduced with vector alone. The third group consists of E2F4 and E2F5, which
generally act to repress E2F-responsive genes, and in our assays demonstrated a strong capacity to inhibit transformation. Our
results imply that the pattern of expression of these six E2F family members in a cell could exert a strong influence over its
susceptibility to oncogenic transformation.
Citation: Chen C, Wells AD (2007) Comparative Analysis of E2F Family Member Oncogenic Activity. PLoS ONE 2(9): e912. doi:10.1371/
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INTRODUCTION
The E2F family of transcription factors consists of nine members
(E2F1, E2F2, E2F3a, E2F3b, E2F4, E2F5, E2F6, E2F7 and E2F8)
with both distinct and overlapping functions (reviewed in [1–3]).
E2F1–6 form heterodimers with DP proteins to achieve high-
affinity DNA binding, while E2F7 and 8 do not require these co-
factors to bind to E2F target genes. E2F proteins are situated at the
‘bottom’ of the growth factor signaling cascade where they
regulate genes involved in cell cycle progression [4,5], and can act
either as transcriptional activators or repressors depending upon
their association with pocket proteins such as pRB [1]. For this
reason, it is likely that the members of the E2F family are
important regulators of oncogenic transformation.
The transforming potential of E2F1–3 has been reported in
various models and cell types, however, a systematic comparison
of E2F1–6 members has not been performed. To make a direct
comparison of oncogenic function among these first six E2F family
members, we have utilized a retroviral approach to generate stable
lines of 3T3 fibroblasts specifically over-expressing E2F1, E2F2,
E2F3a, E2F4, E2F5 or E2F6, and have assessed the ability of these
transgenic cell lines to grow under conditions of low serum, as well
as to form colonies when suspended in soft agar. Our data
demonstrates that E2F2 and E2F3 have strong pro-oncogenic
capacity, whereas E2F4 and E2F5 are anti-oncogenic.
RESULTS
Generation of 3T3 fibroblast lines over-expressing
individual E2F family members
To achieve stable, forced expression of E2F family members 1
through 6 in cells, we constructed bicistronic retroviral vectors
encoding E2F1, E2F2, E2F3a, E2F4, E2F5 and E2F6 (Figure 1 A).
These constructs were able to drive high-level expression of the
NGFR reporter protein (data not shown), as well as specific over-
expression of E2F3a, E2F4, E2F5 and E2F6 protein, respectively,
upon transient transfection of Pheonix/293T cells (Figure 1 B).
E2F1 over-expression was only variably achieved under these
conditions, potentially due to high basal expression of endogenous
E2F1 by Pheonix cells (Figure 1 B, top panel). We also had
difficulty demonstrating E2F2 over-expression in these transient
transfections, either due to low level expression of E2F2 protein, or
relatively low sensitivity of the E2F2-specific antiserum (Figure 1
B, second panel).
E2F-encoding retroviral supernatants produced from these
Pheonix cell transfections were used to transduce non-transformed
NIH 3T3 fibroblasts, and transductants were identified and
purified by the expression of NGFR (Figure 2 A). Transduced 3T3
lines were expanded without selection, and stable NGFR
expression was observed over several weeks in culture (data not
shown). We were able to detect specific over-expression of E2F2
through E2F6 in each respective 3T3 line under conditions of
asynchronous growth, as compared to endogenous expression of
these family members in an empty vector-transduced line (Figure 2
B). However, we were unable to detect over-expression of E2F1 in
actively growing, E2F1-transduced 3T3 cells above that of the
endogenous protein (Figure 2 B).
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asynchronous cell growth
To determine the effect of stable over-expression of individual E2F
family members on asynchronous cell growth, we plated each E2F-
transduced line at low density in high (10%) serum medium, and
enumerated the cells at 24 hour intervals over a four day culture
period. The empty vector-transduced 3T3 line exhibited a consistent
doubling rate of approximately 24 hours until reaching confluency
between 72 and 96 hours (Figure 2 C, gray diamonds). This pattern
of growth closely resembled that of the parental, non-transduced
3T3cells(data not shown). TheE2F1-, E2F2-,andE2F3-transduced
lines exhibited a normal growth rate during the first 48 hours of
culture, but then proliferated at twice the rate of the control cells
until reaching confluency after only 72 hours (Figure 2 C, filled
symbols). Over the next 24 hours, the E2F1- and E2F2-transduced
lines underwent growth arrest (Figure 2 C, filled squares and
triangles), suggesting that these lines are still susceptible to contact
inhibition. However, the E2F3-transduced line continued to grow at
the same rate 24 hours after reaching confluency (Figure 2 C, filled
circles), suggesting that forced expression of E2F3 can overcome
contact inhibition. Unlike the E2F1–3 lines, cells transduced with
E2F4, E2F5 and E2F6 lagged behind the control MINR1 3T3 line,
exhibiting little or no cell growth over the first 48 hours of culture
(Figure 2 C, open symbols). These lines underwent approximately
two doublings during the next 24 hours, but arrested at roughly
72 hours, before reaching 100% confluence. These data suggest that
deregulated expression of E2F4, E2F5 and E2F6 can slow cell cycle
progression and render cells more susceptible to contact inhibition.
Effect of deregulated E2F expression on
serum-independent cell growth
E2F gene expression is normally regulated by signals from growth
factor receptors, and is tightly coordinated with the cell cycle. To
determine the effect of forced expression of individual E2F family
members on cell growth in the relative absence of growth factors,
we plated each E2F-transduced line at medium density in low
(0.1%) serum medium, and monitored E2F family member
expression and cell number over a two day culture period. The
MINR1 empty vector line exhibited very low expression of
endogenous E2F family members following serum withdrawal
(Figure 3 A), while the E2F3–6 transductants exhibited efficient,
serum-independent expression of E2F3, E2F4, E2F5 and E2F6,
respectively (Figure 3 A). Serum deprivation actually induced
accumulation of transgenic E2F1 and E2F2 protein in the E2F1-
and E2F2-transduced lines (Figure 3 A), suggesting that growth
factor-coupled mechanisms that limit E2F1 and E2F2 protein
expression at a post-translational level may be operative during
growth in high serum in our system [6,7].
During the first 16 hours of serum deprivation, control-trans-
duced 3T3 cultures increased in cell number by approximately
50%, but fell precipitously by 30 hours (Figure 3 B, gray
diamonds). These results, along with the initial drop in cell
number at 8 hours, suggest a relatively rapid conversion from cell
growth to cell death in these cultures upon serum withdrawal.
Conversely, 3T3 cells with forced expression of E2F1, E2F2 and
E2F3 continued to grow following serum deprivation (Figure 3 B,
filled symbols). E2F2- and E2F3-transduced cultures continued to
double after 16 hours of serum withdrawal, and maintained at
least two-fold greater cell numbers than control cultures
throughout the 48 hour culture period (Figure 3 B, filled squares
and circles). E2F1-transduced cultures showed a more modest rate
of growth, however, these cultures were also able to maintain
significantly increased cell numbers throughout serum deprivation
as compared to empty vector-transduced cultures (Figure 3 B,
filled triangles). Unlike the lines with forced expression of E2F1, 2
or 3, cell lines transduced with E2F4, E2F5 and E2F6 did not
continue to grow following serum withdrawal, and maintained cell
numbers equal to or less than the control-transduced cultures
throughout the entire response (Figure 3 B, open symbols). These
data show that uncoupling of E2F1, E2F2 and E2F3 expression
from their normal growth factor-mediated regulation is sufficient
to drive a significant degree of growth factor-independent cell
cycle progression, but that E2F4, 5 and 6 cannot mediate this
effect under the same conditions.
Effect of deregulated E2F expression on anchorage-
independent cell growth
The growth of most cells, including fibroblasts, requires integrin-
mediated signals provided through attachment to a solid matrix.
One characteristic of cancer cells is the loss of this requirement,
and such transformed cells gain the capacity to grow in an
anchorage-independent manner [8]. To simulate these conditions
and assess this oncogenic characteristic, we cultured stable E2F-
expressing 3T3 lines in suspension in a semi-solid agarose
medium. In this system, the non-transformed parental 3T3 cell
line exhibited an almost complete requirement for attachment, as
only a few small colonies were observed which did not show
continuous growth when cultures were extended up to two months
(Figure 4 A–C). Positive control H-Ras-transformed N57 cells
generated a high frequency of large colonies that grew pro-
gressively over a one month period (Figure 4 A–C). The empty
MINR1 vector-transduced 3T3 line showed a significant increase
LTR LTR thNGFR IRES E2F cDNA ψ A
Transfectant
A
n
t
i
b
o
d
y
MINR1 E2F1
E2F1
E2F2
E2F2
E2F3
E2F3
E2F4
E2F4
E2F5
E2F5
E2F6
E2F6
1234 67 5
Actin
B
Figure 1. Generation of retroviral vectors encoding E2F family
members. A. Schematic representation of MINR1 retroviral vectors
encoding E2F genes. B. Analysis of E2F family member expression in
transiently-transfected 293T cells. 293T cells were individually trans-
fected with empty (lane 1) or E2F1–6 retroviral plasmids (lanes 2–7), and
extracts were subjected to SDS-PAGE, blotted, and probed for
individual E2F1–6 (top six panels) or actin (bottom panel).
doi:10.1371/journal.pone.0000912.g001
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line (Figure 4 A and B), but unlike the progressive growth of the
N57 colonies, the MINR1-3T3 colonies were small, and had
involuted by day 20 (Figure 4 C). Ectopic expression of E2F1 and
E2F6 in 3T3 cells had a relatively neutral effect on colony
formation as compared to the empty vector-transduced line
(Figure 4 A–C). In contrast, the E2F2- and E2F3-transduced 3T3
lines exhibited strong colony forming capacity. These cells
generated colonies at frequencies approaching the H-Ras-
transformed N57 cells (Figure 4 A and B), with individual colonies
exhibiting strong, exponential growth over the entire one month
culture period (Figure 4 C). Interestingly, ectopic expression of
E2F4 and E2F5 in 3T3 fibroblasts resulted in frequencies of colony
formation that were significantly lower than that of empty vector-
transduced cells, and comparable to that of the non-transformed
parental 3T3 line (Figure 4 A and B). Furthermore, the few
colonies present in these cultures did not grow over time (Figure 4
C). These data suggest that E2F2 and E2F3 have strong oncogenic
capacity, while E2F4 and E2F5 are anti-oncogenic in this system.
E2F1 and E2F6 may be weakly oncogenic, but the background
transforming capacity of the retroviral vector used in these studies
makes our results with these two family members difficult to
interpret.
DISCUSSION
A number of genetic aberrations that promote cancer lead to
deregulated E2F activity [9], including mutations in pRb, cyclinD1,
p16INK4a and CDK4. Although E2F genes are not frequent targets
of mutations in cancer [10], amplification and/or dysregulation of
E2F expression is associated with malignancy in several tumors [11–
13]. By forcing stable, homogeneous expression of individual E2F
family members in non-transformed parental cells, our approach
provides a model of dysregulated E2F expression, and allows an
unprecedented systematic comparison of the oncogenic capacity of
six different E2F family members. Our results show that these six
E2F family members have very different effects on cell growth under
conditions of limiting mitogenic signals.
In our studies, retroviral expression of E2F2 and E2F3
promoted both serum- and contact-independent growth of normal
fibroblasts, consistent with previous in vitro studies in both transient
and stable over-expression systems [14,15]. These data are also
consistent with in vivo studies in which targeted expression of E2F2
or E2F3 in epithelial tissue led to epithelial hyperplasia, and in the
case of deregulated E2F2 expression, led to cortical thymoma
formation [16,17]. In our studies, E2F3a exhibited stronger
transformation activity than E2F2. This may result from the more
stable expression of transgenic E2F3a protein in this system as
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Figure 2. Effect of forced E2F expression on exponential growth of NIH-3T3 cells. A. NIH-3T3 cells were transduced with retroviral constructs
encoding individual E2F1–6, and stained for surface expression of human mutant NGFR. B. Serial 3-fold extracts of stable empty MINR1 (lanes 4–6) or
MINR1-E2F1–6 (lanes 1–3) 3T3 transductants were analyzed for E2F expression as in Figure 1. C. 2610
5 of each transductant (E2F1–3, left panel; E2F4–
6, right panel) was seeded and cultured in full medium with 10% serum. Cultures were counted every 24 hours, and are in thousands. Data are
representative of 2 separate experiments.
doi:10.1371/journal.pone.0000912.g002
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E2F2 may be differentially subject to post-translation control
mechanisms [6]. Also, while E2F1, E2F2 and E2F3a can each
contribute to the initial G0-S phase progression following
stimulation of quiescent cells, E2F3a is the predominant family
member involved in subsequent G1-to-S phase transitions [18],
and has a unique role in centrosome duplication [19]. These
activities may together account for strongest proliferative capacity
of the E2F3a-transgenic fibroblasts in our studies. E2F3b, a splice
variant of E2F3 that contains coding regions unique from E2F3a
[20], was not tested in these studies. This family member might be
expected to be neutral or anti-oncogenic, as E2F3b has been
shown to preferentially bind pRb and repress S-phase genes in
fibroblasts in vitro [21], but further studies will be required to
address the oncogenic capacity of this E2F family member.
Forced expression of E2F4 and E2F5 negatively impacted
fibroblast growth in our experiments, consistent with their defined
roles in enforcing G1 arrest [22]. E2F4 and E2F5 can exhibit
oncogenic activity, but only when expressed together with other
oncogenes such an activated mutant of Ras [11,23]. The empty
MSCV retroviral vector in our studies exhibited measurable
transforming activity in 3T3 fibroblasts, and this was abrogated by
E2F4 and E2F5. These results suggest that these E2F family
members can also have anti-oncogenic or tumor suppressive
activity. Unlike E2F1–3, E2F4 and E2F5 are highly expressed in
quiescent (G0) cells, lack a cyclin A-binding domain, and associate
with p107 and p130 instead of pRB. These factors also lack
nuclear localization domains, and depend upon their association
with pocket proteins for nuclear translocation [23–26]. Conse-
quently, E2F4 and E2F5 commonly act as repressors of E2F
responsive genes [22], which may explain why forced expression of
these factors inhibits proliferation and transformation in our
studies. Two new members of an E2F subfamily, E2F7 and E2F8,
were recently identified after our studies were performed, and like
E2F4 and 5, act as repressors of E2F-induced gene expression and
mitotic progression [27–30]. For this reason we would predict that
these new factors would have anti-oncogenic properties, however,
further studies will be required to address this issue.
E2F1 and E2F6 had weak or no oncogenic capacity compared
to empty vector-transduced cells in our system. E2F6 is unique in
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Figure 3. Capacity of individual E2F family members to support serum-independent growth. 2610
5 asynchronous 3T3 transductants from
exponential cultures were seeded overnight with 10% serum, then cultured in 0.1% serum for the indicated periods, and E2F protein levels (A) and
live cell counts (B) were measured. The data depicted are representative of 2 separate experiments.
doi:10.1371/journal.pone.0000912.g003
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e912Figure 4. Capacity of individual E2F family members to support contact-independent growth. 10
3 E2F-3T3 transductants were seeded in soft agar
medium with 10% serum. Representative 46 fields of N54 (Ras-transformed positive control), empty vector, and E2F1–6 transductant cultures at
30 days are shown in A. The mean colony number per field (+/2 SD) from 10 random fields is plotted in B. The largest colony from each transductant
culture at days 3, 7 and 26 is depicted (206) in C. The data depicted in A–C are representative of 4 separate experiments.
doi:10.1371/journal.pone.0000912.g004
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domains, but lacks the C-terminal transactivation and pocket
protein binding domains characteristic of other members [31–33].
Therefore, E2F6 can act as a competitive inhibitor of DNA
binding by other E2F proteins, and when overexpressed can
oppose the function of both the oncogenic E2F2 and 3a proteins
and the anti-oncogenic E2F4 and 5 family members. This
behavior may explain why E2F6 is neutral in our transformation
assays. E2F6 may also repress pro-mitogenic E2F-responsive
genes, as the C-terminal portion of E2F6 encompassing the
marked-box domain has been shown to inhibit gene transcription
through the recruitment of co-repressor complexes [22,34,35].
This scenario is supported by our in vitro data, in which forced
expression of E2F6 delayed serum-induced cell growth.
In our experiments, forced expression of E2F1 could support
serum-independent growth, which is consistent with previous
studies [36]. Dysregulated E2F1 expression can promote hepato-
cellular adenoma [37], spontaneous epithelial tumors [38], or in
combination with activated ras or p53 deficiency, accelerate skin
tumorigenesis [39,40]. However, this factor was significantly less
efficient in promoting in vitro growth than E2F2 or E2F3 (Figures 2
and 3), and in our soft agar culture system E2F1 exhibited very
weak colony forming activity over control-transduced 3T3
fibroblasts. This weak oncogenic activity could result from post-
translational destabilization of E2F1 through ubiquitination [7],
and indeed we found that E2F1 protein was expressed less
efficiently from the same vector as compared to E2F3 (Figure 3).
These results contrast two previous studies, which showed that
stable over-expression of E2F1 in fibroblasts could induce
measurable contact-independent cell growth [15,41]. One of these
studies generated stably-transfected rat embryonic fibroblast lines
through drug selection, and achieved very high levels of E2F1
expression [41]. The other study utilized a MoMuLV-based vector
[15], which may contribute less background transforming activity
than our MSCV-based vector in these studies, and therefore may
allow detection of weaker oncogenes. In the majority of previous
studies, however, E2F1 activity has been shown to oppose
proliferation and oncogenesis [42,43] through its strong capacity
to activate the p53/73 pathway of intrinsic cell death [44,45],
which likely acts to balance its pro-mitogenic activity in these
assays. Whether the balance of E2F1 activity in a specific tissue
leads to apoptosis and tumor suppression vs. proliferation and
oncogenesis is likely dependent upon the context of pro- vs. anti-
apoptotic signals received by cells at a given time.
In this study, we systematically compared the transforming
activity of E2F family members 1 through 6. Our results show that
these sixE2Ffamilymemberscanbedivided intothree groupsbased
upon their oncogenic capacity in fibroblasts: 1) strong oncogenes
(E2F2and E2F3a),2)weak or neutral genes(E2F1 andE2F6),and 3)
anti-oncogenes (E2F4 and E2F5). The differential capacity of these
E2F factors to promote oncogenic cell growth was associated with
their protein stability, and is likely influenced by their normal
expression patterns and cooperation with other factors.
MATERIALS AND METHODS
Construction of retroviral vectors encoding E2F
proteins
The plasmids pcDNA1-mE2F1 and pBS-mE2F3a were provided
by J. Nevins (Duke Univ.), and plasmids pCMVHA-hE2F2,
pCMVHA-hE2F5, pCMVHA-hE2F6 were provided by K. Helin
(Eur. Inst. Oncology). Full-length E2F cDNA fragments were
subcloned into the EcoRV site of pST-Blue1 vector (Novagene) by
blunt-end ligation. Murine E2F4 cDNA was cloned by RT-PCR
from NIH 3T3 cell lines. Briefly, total RNA was prepared from
10
7 NIH 3T3 cells in RNAstat60 (Tel-test), precipitated in
isopropanol, and dissolved in DEPC-treated water. First strand
cDNA synthesis from 2 mg of total RNA was achieved using
random hexamers and super-reverse transcriptase (Invitrogen).
One-tenth of the RT product was used for PCR using the
following primers: mE2F4 forward primer; 59-CCG GAA TTC
CGG GAT GGC GGA GGC CGG GCC ACA GG-39, mE2F4
reverse primer; 59-CCG GAA TTC CGG GGG TTG CAG CTG
CAC AGG ACA TG-39. The PCR product was cloned into the
EcoRI site of pST-Blue1 vector (Novagen), and confirmed by
sequencing. All E2F cDNAs were subcloned from pST-Blue1 into
the EcoRI cloning site of the MSCV-NGFR expression vector
(MINR1, provided by W. Pear, Univ. Penn.). In this vector, each
E2F ORF is expressed as a bi-cistronic mRNA linked to
a truncated human nerve growth factor receptor (NGFR) reporter
gene by an IRES element, and transduced cells can be identified
by surface expression of NGFR [46]. The general structure of
these vectors is shown in Figure 1 A. All MINR1-E2F inserts were
sequenced using MINR1-specific forward and reverse primers (s5:
59-CCT CCG CCT CCT CTT CCT CCA TCC-39 and a6: 59-
GCC AAA AGA CGG CAA TAT GGT GG-39).
Cell lines
The 293T-based Pheonix ecotropic packaging cell line (provided
by G. Nolan, Stanford Univ.) was used for retroviral vector
production. Gag-pol and env expression was ensured by selection
in medium containing hygromycin and diptheria toxin every three
months. NIH 3T3 cells (ATCC) were maintained in DMEM
medium supplemented with 10% FBS, in 37C and 5% CO2 and
used for E2F cell line generation.
Retrovirus production
Pheonix cells were transiently transfected with MINR1-E2F
retroviral constructs using Lipofectamine 2000 reagent (Invitrogen)
as described by the manufacturer. Briefly, highly confluent Pheonix
cells were co-transfected with a mixture of X mgM I N R 1a n dXmg
pCLeco (Invitrogen) plasmid DNA mixed with Lipofectamine 2000
for4–6 hours.The transfectionmixture wasthenreplaced with fresh
growth medium and the cells were cultured for 48 hours. The
retroviral supernatants were passed through 0.45 mmf i l t e r ,
aliquoted and stored at 270C for future use.
NIH/3T3 cell transductions
NIH 3T3 cells (3610
4) were seeded in 24 well plates, cultured
overnight, and incubated with 1 mL retroviral supernatant in the
presence of 8 mg/ml polybrene (Sigma) at 37C for 18 hours. The
virus-containing medium was replaced with fresh medium and
cells were cultured for an additional 48 hours.
Flow cytometry
Transfections and transductions were monitored by flow cytometry
by surface staining for the hNGFR reporter gene product. Briefly,
Pheonix cells or 3T3 cells were harvested by trypsinization, washed
inPBSwith 1%horseserum,and 5610
5 cells were stainedwithanti-
NGFR-Biotin antibody (BD-Biosciences) at 4C for 30 min. Cells
were washed and stained with streptavidin-PE (BD-Biosciences) at
4C for 30 min. Cells were analyzed on Cyan flow cytometer (Dako).
Serum deprivation and serum stimulation
E2F-3T3 transductants were plated in triplicate at 2610
6 cells in
10 cm dishes. After 24 hours, the cells were washed twice with
E2F Transforming Capacity
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72hr. The cells were then fed with DMEM containing 20% FBS.
At each time point, the cells were harvested by trypsin treatment
and counted using a hemocytometer.
Immunoblot analysis
E2F-3T3 cells (2610
5) were boiled in reducing Laemmli buffer
and subjected to SDS-PAGE. Cellular proteins were transferred to
nitrocellulose membranes and probed with specific antisera
specific for E2F1, E2F2, E2F3a/b, E2F4, E2F5 and E2F6 (Santa
Cruz). Immunoreactive proteins were detected with HRP-
conjugated secondary antibody (Jackson Immunoresearch) and
visualized using chemiluminescence (BioRad).
Semi-solid agar culture of E2F-3T3 cell lines
Actively growing 3T3 cells (1610
3) were mixed with pre-warmed
medium supplemented with 0.3% agarose (type VII, Sigma),
plated onto solidified medium containing 0.5% agarose in 6-well
plates, and cultured at 37C in 5% CO2. Top agarose was
replenished every two weeks. Colony formation was monitored
and enumerated by counting 10 random 106fields.
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